CEO Executive AssistantThe contract vs full-time virtual EA decision for pharmaceutical and biotech CEOs involves more than scheduling flexibility. It involves questions of institutional knowledge accumulation, operational reliability during critical periods, and the cost structure that best matches the variable demands of a drug development or commercialization operation.
Both models can serve pharmaceutical executives effectively. The right choice depends on the specific rhythms and demands of your role.
Defining the Models
In the context of virtual EA services, “contract” typically means month-to-month engagement without a committed annual term. You pay as you go, can scale up or down, and can exit the arrangement without penalty if your needs change.
“Full-time” typically refers to a committed, ongoing engagement providing 35 to 40 hours of EA support per week. This may come with an annual service agreement, a dedicated EA who works exclusively for you, and a deeper investment in the relationship from both sides.
The distinction is not always about the EA’s employment status (contractor vs. employee). It is primarily about the commitment structure and coverage level.
The Case for Contract Virtual EA Support
Contract arrangements give pharmaceutical CEOs operational flexibility that fixed full-time commitments cannot match.
Variable Operational Tempo: Drug development is not a consistent workload. The weeks before an ANDA submission, during a Phase 3 readout, or ahead of a major medical conference generate intense administrative demands. Other periods are comparatively quiet. A contract arrangement lets you scale EA hours to match operational tempo rather than paying for full-time coverage when you do not need it.
Lower Financial Commitment: Monthly contracts allow you to evaluate the relationship before committing long-term. For pharmaceutical executives who have had inconsistent EA experiences in the past, this lower commitment threshold enables a more careful evaluation.
Faster Exit if Needed: If the EA relationship does not meet your needs, a monthly contract allows you to exit or switch providers without penalty or contractual complexity.
The trade-off is cost. Contract arrangements typically carry a 15 to 25 percent per-hour premium over annual commitments. For pharmaceutical CEOs with consistent, ongoing needs, that premium adds up over a year.
The Case for Full-Time Virtual EA Support
Full-time committed support offers the pharmaceutical CEO something the contract model cannot: depth.
Institutional Knowledge Accumulation: A full-time dedicated EA builds extensive knowledge of your regulatory calendar, investor relationships, internal team dynamics, and communication preferences over time. After six to twelve months, a strong full-time EA anticipates your needs rather than responding to requests. That level of operational integration creates genuine leverage.
Priority Access and Availability: Full-time EAs prioritize your work over other clients because your engagement represents their primary or exclusive commitment. In a contract or shared arrangement, your EA may also be supporting other executives, which can create availability gaps at inconvenient moments.
Consistency During Critical Periods: When you are managing an NDA submission timeline, preparing for an advisory committee meeting, or navigating a financing round, you need consistent, reliable support. Full-time coverage ensures your EA is available and engaged regardless of timing.
Cost Efficiency at Scale: At 35 to 40 hours per week, full-time arrangements at managed services typically carry a lower effective hourly rate than part-time or contract arrangements. If you actually need that level of support, the full-time model is more economical per hour.
What Pharmaceutical CEOs Typically Find
In practice, pharmaceutical and biotech CEOs who start with contract arrangements frequently transition to full-time or near-full-time commitments within six to twelve months. The reason is consistent: once you experience well-calibrated EA support in a pharmaceutical environment, the value of depth over flexibility becomes apparent.
The CEOs who maintain contract arrangements long-term tend to have operations where administrative needs are genuinely variable and where the peaks are not so high that they require continuous full-time support.
For a comparison of specific service options across both contract and full-time models, see remote EA for pharma. For dedicated full-time service options specifically, dedicated EA for pharma covers that segment in detail.
Cost Comparison at Equivalent Hours
To compare contract vs. full-time pricing honestly, normalize to the same number of hours.
A managed service offering contract month-to-month arrangements might charge $75 per effective hour for 20 hours per week, totaling $6,000 per month.
The same service offering a committed annual engagement might charge $60 per effective hour for the same 20 hours per week, totaling $4,800 per month, a savings of $1,200 per month or $14,400 per year.
At 40 hours per week with the same rate differential, the annual savings from a committed arrangement versus month-to-month can exceed $25,000.
For pharmaceutical CEOs with stable, ongoing support needs, that cost differential is significant. For executives with genuinely variable needs, the flexibility premium may be worth paying.
Factors That Should Push You Toward Full-Time
These operational characteristics suggest a full-time arrangement is likely more appropriate.
Active Investor Program: Managing 20 or more institutional investor relationships requires consistent EA support for meeting logistics, communications management, and investor day preparation. This is not a part-time function.
Multiple Active Clinical Programs: CEOs overseeing multiple parallel development programs have complex, overlapping calendars that require deep EA context to manage effectively.
Global Operations: International partnership structures, multi-site operations, or cross-border regulatory engagements create time zone complexity that benefits from full-time EA coverage across extended hours.
Board Governance Intensity: Frequent board meetings, committee meetings, and board-level stakeholder communications require an EA who is deeply embedded in your governance calendar.
Research Context: Depth vs. Flexibility in Support
Research from Harvard Business Review consistently shows that the greatest executive productivity gains from administrative support come from deep, stable relationships where the EA has accumulated substantial context about the executive’s priorities and working style. That depth is a product of full-time commitment and time together, not of flexible contract arrangements.
For pharmaceutical CEOs, this research finding is especially relevant. Your operation is complex enough that an EA without deep context is a limited asset. An EA with twelve months of deep immersion in your regulatory calendar, investor program, and organizational dynamics is a significant force multiplier.
Conclusion
The contract vs full-time virtual EA decision for pharmaceutical and biotech CEOs comes down to operational complexity and horizon. If your support needs are highly variable and your time horizon is uncertain, a contract arrangement gives you flexibility. If your operation is active, complex, and ongoing, the full-time model’s depth, institutional knowledge accumulation, and cost efficiency at scale make it the stronger choice. Most pharmaceutical CEOs managing active pipelines benefit from the full-time commitment, and many who start with contract arrangements transition to full-time once they experience the difference.
Related Reading
For further context, explore Contract vs Full-Time Virtual EA for Automotive CEOs and Contract vs Full-Time Virtual EA for Construction & Architecture CEOs.